Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition

• The transaction is expected to close in mid-2026, the company said.
• Of the $1.15 billion, about $240 million in cash will be paid at closing of the transaction.
• Eucalyptus CEO Tim Doyle will join Hims & Hers as senior vice president of International.

Hims & Hers Health, Inc. (HIMS) announced on Thursday that it has signed a definitive agreement to acquire Eucalyptus in a deal valued at up to $1.15 billion.

HIMS shares pared most of their gains after the opening bell and were trading 0.5% higher at the time of writing 

Eucalyptus Acquisition Marks Expansion Into Australia and Japan

The transaction, expected to close in mid-2026, will strengthen the company’s ability to deliver personalized digital healthcare internationally, Hims & Hers said.

Upon completion, Hims & Hers plans to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. Eucalyptus CEO Tim Doyle will join Hims & Hers as senior vice president (SVP) of International, and Eucalyptus’ brands will gradually transition to the Hims & Hers platform.

“We've shown the difference that makes in the US, and the logical next step is working with more international experts to make that difference abroad,” said Andrew Dudum, founder and CEO of Hims & Hers. 

$240 Million To Be Paid At Transaction’s Close

Out of the $1.15 billion, about $240 million in cash will be paid at closing, with the remaining consideration comprising guaranteed deferred payments over 18 months and additional earnouts tied to financial targets through early 2029. 

Hims & Hers said it can pay most deferred and earnout amounts in cash or stock and expects to fund the deal primarily with existing cash and future U.S. operating cash flow.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier. 

One user expects margins and cash flow to “plummet”.

Another user sees consolidation amid fading selling pressure.

Year-to-date, the stock has declined more than 50%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on